Want to see GB:GSK full AI Analyst Report?
Top Page
GlaxoSmithKline
(LSE:GSK)
Select Model
Select Model
Rating:73Outperform
Price Target:
2,238.00 p
▲(17.45% Upside)
Action:Reiterated
Date:07/30/26
The score is driven primarily by strong profitability and solid free-cash-flow generation, supported by reasonable valuation and an attractive dividend yield. The main constraints are balance-sheet leverage and uneven earnings/cash conversion, while technicals are moderately positive based on price being above major moving averages (with limited momentum data available).
Positive Factors
Strong Profitability
High gross and operating margins indicate valuable branded medicines and vaccines, pricing power, and operating scale. These characteristics can support resilient earnings and fund ongoing research, manufacturing investment, and commercial expansion.
Negative Factors
Meaningful Leverage
Debt roughly matching equity leaves GSK more reliant on borrowing than conservatively financed peers. Elevated leverage can constrain investment flexibility and increase refinancing sensitivity if profitability weakens or interest costs remain elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
High gross and operating margins indicate valuable branded medicines and vaccines, pricing power, and operating scale. These characteristics can support resilient earnings and fund ongoing research, manufacturing investment, and commercial expansion.
Read all positive factors
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£70.94B
Dividend Yield3.84%
Average Volume (3M)5.29M
Price to Earnings (P/E)14.8
Beta (1Y)1.15
Revenue Growth4.97%
EPS Growth42.62%
CountryUK
Employees66,841
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.20
Shares Outstanding4,045,421,400
10 Day Avg. Volume4,259,013
30 Day Avg. Volume5,294,266
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,089.62Price Target Upside9.66% Upside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)1.78
Revenue Forecast (FY)£33.85B
GlaxoSmithKline Business Overview & Revenue Model
Company Description
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United St...
How the Company Makes Money
GSK primarily makes money by selling branded prescription medicines and vaccines. Revenue is generated when its products are purchased by wholesalers and distributors, pharmacies, hospitals/clinics, and government or public-health buyers (particul...
GlaxoSmithKline Earnings Call Summary
Earnings Call Date:Jul 28, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 28, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum with several clear positives: record infrastructure EBITDA, meaningful marketing outperformance, improved distributable cash flow, successful acquisition and active growth projects, cost savings initiatives, and reinforced liquidity and ratings. Offsetting items are primarily near-term and transitional: export market volatility (freight/vessel availability) affecting gateway volumes and contracting, temporarily elevated leverage and dividend payout due to timing of the Chauvin acquisition, and some weaker asphalt demand. Management provided visibility on actions to deleverage (targeting early 2027), plans for FIDs (notably Chauvin expansion), and expects sustainable cost savings, positioning the company for continued execution. Overall, highlights materially outweigh the lowlights.Positive Updates
Record Infrastructure Adjusted EBITDA
Infrastructure adjusted EBITDA reached CAD 169 million in Q2 2026, an increase of CAD 17 million (+11.2%) versus Q2 2025 and CAD 9 million higher than the prior record set in Q4 2025. Stronger utilization, contribution from the Chauvin acquisition, and ~8 million additional barrels of throughput YoY drove the result.
Negative Updates
Market Volatility Impacting Gateway Volumes
Geopolitical uncertainty, commodity volatility, elevated freight rates and constrained vessel availability have temporarily impacted gateway volumes and made cargo scheduling and long-term contracting more challenging in the export market.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Infrastructure Adjusted EBITDA
Infrastructure adjusted EBITDA reached CAD 169 million in Q2 2026, an increase of CAD 17 million (+11.2%) versus Q2 2025 and CAD 9 million higher than the prior record set in Q4 2025. Stronger utilization, contribution from the Chauvin acquisition, and ~8 million additional barrels of throughput YoY drove the result.
Read all positive updates
Company Guidance
Management reiterated its near‑term and medium‑term guidance while providing numerous metrics: Q2 infrastructure adjusted EBITDA hit a record CAD169M (up CAD17M YoY and CAD9M above the prior record), consolidated adjusted EBITDA was CAD169M (up CAD22M YoY), marketing EBITDA was CAD15M in Q2 (vs CAD8M in Q2‑2025) with YTD marketing CAD18M and trending to the upper end of the CAD0–40M full‑year range from Investor Day; distributable cash flow was CAD96M (up CAD15M YoY); Q2 G&A was CAD16M (below guidance of CAD17–18M) with ~CAD10M of sustainable annualized savings expected in 2027; throughput rose by ~8 million barrels YoY; net debt/adjusted EBITDA was 4.2x (infrastructure leverage 4.4x; pro forma with a full 12 months of Chauvin 3.9x overall and 4.1x infrastructure) and management expects leverage to return to the 3.0–3.5x target in early 2027; dividend payout exited the quarter at a sustainable 88% (infrastructure‑only 83% vs a 100% target); the CAD1B revolver was extended to June 2031 and CAD400M of senior notes were issued; the Chauvin acquisition closed May 1 with a planned Hardisty connection in H1‑2027 and an engineered expansion to raise capacity 50% from 30k to 45k bpd under review, Wink‑to‑Gateway is on track for in‑service by end‑Q3, and management remains on track to pursue the >CAD1B of growth capital opportunities discussed at Investor Day.GlaxoSmithKline Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.20B | 32.67B | 31.38B | 30.33B | 29.32B | 24.70B |
| Gross Profit | 24.33B | 23.70B | 21.90B | 21.25B | 19.46B | 16.34B |
| EBITDA | 10.95B | 11.88B | 6.67B | 9.14B | 8.63B | 6.45B |
| Net Income | 4.82B | 5.72B | 2.58B | 4.93B | 14.96B | 4.38B |
Balance Sheet | ||||||
| Total Assets | 61.74B | 61.12B | 59.46B | 59.01B | 60.15B | 79.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.11B | 3.16B | 3.71B | 5.69B | 7.68B | 4.13B |
| Total Debt | 18.24B | 17.72B | 16.99B | 18.02B | 20.99B | 24.17B |
| Total Liabilities | 44.56B | 45.16B | 46.38B | 46.21B | 50.05B | 57.76B |
| Stockholders Equity | 17.64B | 16.38B | 13.67B | 13.35B | 10.60B | 15.05B |
Cash Flow | ||||||
| Free Cash Flow | 5.76B | 5.96B | 3.57B | 4.42B | 5.14B | 5.02B |
| Operating Cash Flow | 7.98B | 7.30B | 6.55B | 6.77B | 7.40B | 7.95B |
| Investing Cash Flow | -6.29B | -5.85B | -1.23B | -1.59B | -8.77B | -1.78B |
| Financing Cash Flow | -2.12B | -1.63B | -4.73B | -5.64B | 823.00M | -7.59B |
GlaxoSmithKline Technical Analysis
Negative
1905.50
Price Trends
1895.19
Negative
1900.08
Negative
1919.03
Negative
Market Momentum
-29.89
Positive
32.21
Neutral
8.51
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GSK, the sentiment is Negative. The current price of 1905.5 is above the 20-day moving average (MA) of 1857.13, above the 50-day MA of 1895.19, and below the 200-day MA of 1919.03, indicating a bearish trend. The MACD of -29.89 indicates Positive momentum. The RSI at 32.21 is Neutral, neither overbought nor oversold. The STOCH value of 8.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GSK.
GlaxoSmithKline Risk Analysis
GlaxoSmithKline disclosed 1 risk factors in its most recent earnings report. GlaxoSmithKline reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlaxoSmithKline Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £3.17B | 11.57 | 15.05% | 4.14% | 2.48% | 3.36% | |
73 Outperform | £70.94B | 14.75 | 28.35% | 3.84% | 4.97% | 42.62% | |
72 Outperform | £8.44B | 17.94 | 12.25% | 2.88% | 2.17% | 27.33% | |
70 Outperform | £181.58B | 23.60 | 21.68% | 2.04% | 4.71% | 21.16% | |
66 Neutral | £29.36B | 18.40 | 9.89% | 2.19% | 1.21% | 8.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GB:GSK
GlaxoSmithKline
1,770.50
342.33
23.97%
GB:AZN
AstraZeneca
11,708.00
485.75
4.33%
GB:HIK
Hikma Pharmaceuticals
1,531.00
-4.38
-0.29%
GB:SN
Smith & Nephew
1,008.50
-344.49
-25.46%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
62.50
18.07
40.68%
GB:HLN
Haleon PLC
333.80
-15.81
-4.52%
GlaxoSmithKline Corporate Events
DividendsRegulatory Filings and Compliance
GSK Executives Add ADS Through Dividend Reinvestment Plans
Positive
Aug 18, 2026
GSK disclosed several routine share transactions by senior executives involving the acquisition of American Depositary Shares through dividend reinvestment in company savings and supplemental plans. Non‑Executive Director Hal Barron, SVP and...
Other
GSK Executives Acquire Shares Under Company Reward Plan
Positive
Aug 13, 2026
GSK has disclosed a series of routine share dealings by several senior executives, including its CFO, regional presidents and other top managers, who each acquired 14 ordinary shares under the company’s Share Reward Plan. The purchases, all ...
Executive/Board ChangesRegulatory Filings and Compliance
GSK Discloses Executive Notional ADS Acquisition by U.S. President
Neutral
Aug 11, 2026
GSK plc disclosed a transaction involving Maya Martinez-Davis, its President for the U.S. business, who acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan. The purchase, executed on 7 August 2026 on th...
Regulatory Filings and Compliance
GSK Updates Market on Total Voting Rights and Share Capital
Neutral
Aug 3, 2026
GSK has reported that as of 31 July 2026 its issued share capital comprised more than 4.3 billion ordinary shares, of which around 271 million are held in treasury, resulting in a total of 4.045 billion voting rights. The disclosure, made under UK...
Regulatory Filings and Compliance
GSK Supply Chain President Registers Sale of Ordinary Shares
Neutral
Jul 30, 2026
GSK disclosed that Regis Simard, the company’s President of Global Supply Chain, has sold 38,000 ordinary shares in the group. The transaction, executed on July 29, 2026 on the London Stock Exchange at £20.38 per share, reflects routine...
Business Operations and Strategy
GSK commits £400m to new Cambridge R&D hub in UK life sciences ‘Golden Triangle’
Positive
Jul 28, 2026
GSK will build a new 300,000 square foot flagship RD centre on the Cambridge Biomedical Campus, consolidating its UK research operations and housing more than 1,000 scientists. The move embeds the company deeper into the UK’s ‘Golden T...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
GSK lifts core earnings as it accelerates R&D and tightens costs
Positive
Jul 28, 2026
GSK reported second-quarter 2026 sales of £8.4 billion, up 5% at constant exchange rates, driven by double-digit growth in specialty medicines and an 8% rise in vaccines, even as general medicines declined. Core operating profit grew 7% and c...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology push
Positive
Jul 28, 2026
GSK’s licensor Hansoh Pharma has reported that its phase III ARTEMIS-011 trial of risvutatug rezetecan (Ris-Rez) in Chinese patients with relapsed osteosarcoma achieved a statistically significant improvement in progression-free survival ver...
Business Operations and StrategyProduct-Related Announcements
GSK Wins First U.S. Lung Cancer Nod With ROS1 Drug Jideytro
Positive
Jul 22, 2026
GSK has secured its first U.S. approval in lung cancer with the FDA greenlighting Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor....
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GSK Seeks EMA Nod for Bexsero Booster to Extend MenB Protection
Positive
Jul 20, 2026
GSK has announced that the European Medicines Agency has accepted its submission to update the label of Bexsero to include a single-dose booster for individuals aged 10 and older who were previously vaccinated with the meningococcal B vaccine in i...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
GSK to retain Deloitte as external auditor from 2028 after tender review
Neutral
Jul 17, 2026
GSK plc has concluded a competitive tender process for its statutory audit and the Board has decided to re-appoint Deloitte LLP as external auditor from the financial year ending 31 December 2028. The move reflects the company’s obligations ...
Business Operations and StrategyProduct-Related Announcements
GSK Halts Camlipixant Development in Chronic Cough After Mixed Phase III Results
Negative
Jul 17, 2026
GSK has reported mixed phase III results for its P2X3 receptor antagonist camlipixant in adults with refractory chronic cough, a condition with limited existing treatments. While the CALM-1 trial met its primary endpoint at 12 weeks with the 50mg ...
DividendsRegulatory Filings and Compliance
GSK executives boost holdings via dividend-funded ADS purchases
Neutral
Jul 16, 2026
GSK has disclosed a series of transactions in which several senior executives and non-executive directors acquired American Depositary Shares through the reinvestment of dividends recently paid to shareholders. The ADS purchases, executed on the N...
Business Operations and StrategyM&A Transactions
GSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer Push
Positive
Jul 15, 2026
GSK has completed its acquisition of Nuvalent, Inc., a clinical-stage oncology specialist, in a deal valuing the U.S. company’s equity at about $10.6 billion. The transaction adds three targeted non-small cell lung cancer assets to GSK’...
DividendsRegulatory Filings and Compliance
GSK Executives Reinvest Dividends in Routine Share Purchases
Neutral
Jul 14, 2026
GSK has disclosed a series of routine share transactions by several senior executives, including CEO Luke Miels and regional and functional presidents, who acquired small numbers of ordinary shares via the automatic reinvestment of dividends paid ...
Business Operations and StrategyRegulatory Filings and Compliance
GSK Executives Acquire Shares Under Routine Reward Plan
Positive
Jul 13, 2026
GSK has disclosed multiple small share acquisitions by senior executives under the company’s Share Reward Plan, all involving purchases of 12 ordinary shares each at £19.629 on 9 July 2026. The transactions, conducted on the London Stoc...
Business Operations and StrategyProduct-Related Announcements
GSK’s Jemperli Trial Points to Chemo‑Free Future for Subset of Rectal Cancer Patients
Positive
Jul 13, 2026
GSK has reported positive interim phase II AZUR-1 data for its PD‑1 inhibitor Jemperli (dostarlimab) in stage II/III dMMR/MSI‑H locally advanced rectal cancer, achieving a meaningful, sustained clinical complete response at 12 months. ...
Business Operations and Strategy
GSK’s Partner Delivers Landmark Lung Cancer Data for B7-H3 ADC
Positive
Jul 10, 2026
GSK’s licensor Hansoh Pharma has reported that the pivotal ARTEMIS-008 phase III trial of risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer patients in China met its primary endpoint, showing statistically signifi...
Business Operations and StrategyExecutive/Board Changes
GSK US President Acquires Notional ADS Under Executive Savings Plan
Positive
Jul 9, 2026
GSK disclosed that Maya Martinez-Davis, President of US operations and a person discharging managerial responsibilities, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan. The transaction, conducted o...
Business Operations and StrategyExecutive/Board Changes
GSK Adds Philips CEO Roy Jakobs to Board as Independent Director
Positive
Jul 9, 2026
GSK has appointed Roy Jakobs, the current chief executive of health technology group Royal Philips, as an independent non-executive director on its board effective 13 July 2026. The board says Jakobs’ background in patient monitoring, imagin...
Regulatory Filings and Compliance
GSK Updates Market on Total Voting Rights as of 30 June 2026
Neutral
Jul 1, 2026
GSK has reported that, as of 30 June 2026, its issued share capital comprises 4,316,276,428 ordinary shares, of which 270,881,064 are held in treasury, resulting in 4,045,395,364 voting rights. This updated voting rights figure provides investors ...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK Completes £2 Billion Share Buyback, Lifts Treasury Holdings to 6.7% of Voting Rights
Positive
Jun 29, 2026
GSK has completed a share buyback programme of up to £2 billion, executed through Citigroup Global Markets, with recent purchases between 22 and 26 June 2026 to be held in treasury. Since the programme was announced in February 2025, the comp...
Regulatory Filings and Compliance
GSK Discloses Executive Notional ADS Acquisition by U.S. President
Neutral
Jun 24, 2026
GSK has disclosed a transaction involving Maya Martinez-Davis, President of its U.S. business, who acquired notional American Depositary Shares through her Executive Supplemental Savings Plan. The purchase, executed on the New York Stock Exchange ...
Business Operations and StrategyM&A Transactions
GSK launches $124-per-share tender offer to acquire oncology developer Nuvalent
Positive
Jun 24, 2026
GSK has launched a cash tender offer, through its subsidiary Harmony Row Acquisition Co., to acquire all outstanding Class A and Class B shares of Nuvalent at $124 per share, under a previously agreed merger plan. Following a successful offer, Har...
Other
GSK board members boost holdings with coordinated share purchases
Positive
Jun 23, 2026
GSK has disclosed a series of share purchases by its senior board members, including Non-Executive Chair Sir Jonathan Symonds, who acquired 1,550 ordinary shares on the London Stock Exchange. The transactions underscore direct board-level exposure...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK Expands Treasury Stock Position with June Share Buybacks
Positive
Jun 22, 2026
GSK has continued its ongoing share buyback programme, repurchasing more than one million ordinary shares between 15 and 19 June 2026 through Citigroup Global Markets and holding the acquired stock in treasury to manage its capital structure. Foll...
Business Operations and StrategyProduct-Related Announcements
GSK wins first US approval for oral carbapenem to treat complicated UTIs
Positive
Jun 17, 2026
GSK and Spero Therapeutics have secured US FDA approval for Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternativ...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK Expands Share Buyback, Lifts Treasury Holding to 6.64% of Voting Rights
Positive
Jun 15, 2026
GSK has continued to execute its existing share buyback programme, repurchasing more than 1.1 million ordinary shares between 8 and 12 June 2026 through Citigroup Global Markets at volume-weighted average prices ranging from 1,882.23p to 1,983.00p...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome
Positive
Jun 12, 2026
GSK has secured Orphan Drug Designation from both the U.S. and European regulators for momelotinib in VEXAS syndrome, a rare, life‑threatening clonal myeloid disorder with no approved therapies and high five‑year mortality. The drug, a...
Other
GSK Executives Acquire Shares Under Company Reward Plan
Neutral
Jun 11, 2026
GSK disclosed that several senior executives, including President Europe Lynn Baxter and Chief Financial Officer Julie Brown, acquired ordinary GSK shares on 9 June 2026 through the company’s Share Reward Plan at £18.8393 per share. Add...
Business Operations and StrategyExecutive/Board Changes
GSK US President Acquires Notional ADS Under Executive Savings Plan
Positive
Jun 10, 2026
GSK disclosed that Maya Martinez-Davis, its President of U.S. operations, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan. The transaction, conducted on June 8, 2026 on the New York Stock Exchange, ...
Business Operations and StrategyExecutive/Board Changes
GSK Director Hal Barron Takes Governance Role at Quantinuum
Positive
Jun 9, 2026
GSK has announced that non-executive director Dr Hal Barron has been appointed an independent director and chair of the Nominating and Corporate Governance Committee at Quantinuum Inc. This additional leadership role for Barron could strengthen GS...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
GSK to buy Nuvalent in $10.6bn deal to fast-track lung cancer push
Positive
Jun 9, 2026
GSK has agreed to acquire Boston-based clinical-stage oncology specialist Nuvalent for $10.6 billion, securing three lung cancer assets, including late-stage ROS1 and ALK inhibitors zidesamtinib and neladalkib, as well as a HER2 inhibitor and a br...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK Boosts Treasury Stock with Latest Share Buyback Tranche
Positive
Jun 8, 2026
GSK has continued its existing share buyback programme, repurchasing more than 1.6 million ordinary shares between 1 and 5 June 2026 through Citigroup Global Markets, with the acquired stock to be held as treasury shares. The move increases total ...
Business Operations and StrategyStock Buyback
GSK boosts treasury stock as buyback lifts voting share base
Positive
Jun 1, 2026
GSK has continued its share buyback programme, repurchasing just under 1.25 million ordinary shares between 26 and 29 May 2026 through Citigroup Global Markets. The shares, which will be held in treasury, were bought at volume-weighted average pri...
Regulatory Filings and Compliance
GSK Updates Market on Total Voting Rights and Share Capital
Neutral
Jun 1, 2026
GSK has reported that as of 31 May 2026 its issued share capital stood at 4,316,224,814 ordinary shares, of which 265,968,706 are held in treasury. This leaves a total of 4,050,256,108 voting rights, a key figure investors must use to assess and d...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GSK’s bepirovirsen delivers landmark functional cure rates in chronic hepatitis B phase III trials
Positive
May 28, 2026
GSK reported pivotal phase III data showing its investigational antisense oligonucleotide bepirovirsen achieved a 19% functional cure rate in adults with chronic hepatitis B with baseline surface antigen levels ≤3000 IU/mL, compared with 0% ...
Regulatory Filings and Compliance
GSK Discloses Notional ADS Purchase by US President Martinez-Davis
Neutral
May 27, 2026
GSK plc disclosed that Maya Martinez-Davis, its President for the US, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction, executed on 22 May 2026 on the New York Stock Exchange...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK boosts treasury stock as buyback programme passes 3.3 million shares
Positive
May 26, 2026
GSK has continued its share buyback programme, repurchasing around 1.67 million ordinary shares between 18 and 22 May 2026 through Citigroup Global Markets, with prices ranging from 1,847p to 1,927p per share. The repurchased shares will be held i...
Business Operations and StrategyRegulatory Filings and Compliance
GSK Adds Shares to Market Under Employee Save Plan
Neutral
May 26, 2026
GSK has admitted 45,273 new ordinary shares of 31¼ pence each to trading on the London Stock Exchange’s Main Market under its existing block listing for the GlaxoSmithKline plc Share Save Plan 2022. The new shares are fully fungible wit...
Business Operations and StrategyDividendsFinancial Disclosures
GSK Sets 2026 Results and Dividend Timetable, Plans Portfolio Growth Update
Positive
May 22, 2026
GSK plc has confirmed it will publish its Q2 2026 results on 28 July 2026 via the London Stock Exchange, alongside an update on portfolio growth opportunities that may signal strategic priorities for its vaccine and specialty medicines businesses....
Regulatory Filings and Compliance
GSK Discloses Routine ADS Purchase by Non-Executive Director Hal Barron
Neutral
May 20, 2026
GSK disclosed that non-executive director Dr. Hal Barron acquired American Depositary Shares of the company through the reinvestment of dividends in his GSK 401(k) plan account. The transaction, involving 74 ADS at a price of $49.67 each, took pla...
DividendsRegulatory Filings and Compliance
GSK Executives Add Notional ADS Through Dividend Reinvestment Plan
Neutral
May 19, 2026
GSK has disclosed a series of routine insider transactions involving senior leadership, including non‑executive director Dr Hal Barron, SVP and group general counsel James Ford, and US president Maya Martinez‑Davis. Each executive acqu...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
GSK Adds 1.7 Million Shares to Treasury in Ongoing Buyback Programme
Positive
May 18, 2026
GSK has repurchased 1,671,851 ordinary shares between 11 and 15 May 2026 under its ongoing share buyback programme, with the shares to be held in treasury. Following these transactions, GSK now holds 263,050,137 shares in treasury, representing 6....
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GSK Wins Wider Japanese Approval for RSV Vaccine Arexvy in At-Risk Adults
Positive
May 18, 2026
GSK has secured expanded approval in Japan for its RSV vaccine Arexvy, which can now be used in adults aged 18-49 at increased risk of RSV disease, in addition to existing approvals in adults 50 and older, including all over 60. Japan’s upda...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.